The Indication monitors the regulatory firehose automatically and adds the one thing no competitor in Canada offers: the insider read on what each decision means for distribution, reimbursement, and channel strategy.
Canadian pharma trade coverage is fragmented. The beat is split across generalist business outlets, a few dated newsletters, and US publications that treat Canada as a footnote. The decisions that actually move the market — pCPA outcomes, PMPRB rulings, provincial formulary listings, CADTH/INESSS recommendations, and the specialty distribution layer most journalists don’t even know exists — get fast, interpreted coverage almost nowhere.
That gap is the entire reason this exists. Public announcements are a commodity; the read on what a pCPA decision means for the channel is not. The moat is interpretation, not aggregation.
Monitoring and first-draft structuring are automated — Health Canada NOCs, PMPRB updates, pCPA moves, and HTA recommendations are tracked as they land. Then a human adds the part that matters: the insider interpretation. That’s the irreplaceable step, and it’s what makes the work both worth reading and able to rank in a category Google scrutinises heavily.
Automated ingestion of the Canadian regulatory firehose, surfaced in The Wire as it happens.
A human writes the two paragraphs nobody else in Canada can — the channel and reimbursement read.
Free to read with an account; queryable inside your AI assistant via the Connector.
Seven years inside Canadian specialty pharma at McKesson — the vantage point this publication is built on. The Indication is solo-run by design, built to read like an institution, and focused on the channel realities that decision-makers actually price into their work.
Create a free account to read every analysis in full, or put The Indication inside your AI assistant.